Review Article
Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
Table 4
Selected clinical trials using dendritic cells (DCs).
| Reference | Patients | Immunologic response | Clinical response |
| [155] | (GBM: 6, AA: 1) | Cytotixic and memory T cells found in recurrent tumor bulk | Median survival: 455 days (Control group: 257 days) | [156] | (GBM: 7, Recurrent GBM: 5) | Cytotoxicity against autologous tumor cells. Cytotoxic T cells found in recurrent tumor bulk. | Median TTP: 19.9 mo (), Median survival: 35.8 mo () | [157] | EGFRvIII expressing GBM | 82% of recurrent tumors lost EGFRvIII expression | Median survival: 26 mo () | Others: [80, 84, 158–173] | | | |
|
|